Virilitas Labs secures £100k from Anglia Capital Group to develop male fertility tests.
Anglia Capital Group backs Norwich-based Virilitas Labs with a £100k investment.
Share allotment filed at Companies House
Norwich-based Virilitas Labs develops rapid, at-home male fertility tests that use artificial intelligence for analysis.
Virilitas Labs has secured £100k in funding from Anglia Capital Group to advance its male reproductive health technology. The capital will be allocated towards strengthening the company intellectual property portfolio, refining its rapid-testing diagnostics, and building out its digital application.
Co-founded by Daniel Marcu and Simone Immler, the Norwich-based enterprise focuses on improving access to male fertility diagnostics to reduce delays in treatment. The latest backing follows selection for Innovate UK programmes, positioning the business for broader commercial development.
Investor perspective
"The founders demonstrated a strong grasp of the clinical and commercial needs in this space. Their technology addresses an important issue that resonates strongly with our investors, who are committed to backing impactful innovation. We’re thrilled to welcome Virilitas Labs into the ACG portfolio and support their next stage of growth."
Laura Hood
Operations Director, Anglia Capital Group
Use of funds
- 01Continue product development
- 02Build out infrastructure
Investors
Categories
About the company
Virilitas Labs
Virilitas Labs creates at-home male fertility tests supported by artificial intelligence.